Genetic testing and counseling challenges in personalized breast cancer care: review article with insights from Türkiye

Basit Öğe Kaydı
dc.authoridCicin, Irfan/0000-0002-7584-3868
dc.authoridDEMIRCI, UMUT/0000-0002-4833-6721
dc.authoridsezgin goksu, sema/0000-0002-1222-0444
dc.authoridBisgin, Atil/0000-0002-2053-9076
dc.authorwosidSendur, Mehmet Ali Nahit/H-7555-2014
dc.authorwosidER, OZLEM/X-1330-2018
dc.authorwosidsezgin goksu, sema/C-1941-2016
dc.contributor.authorCicin, Irfan
dc.contributor.authorKaradurmus, Nuri
dc.contributor.authorBilici, Ahmet
dc.contributor.authorBahsi, Taha
dc.contributor.authorSendur, Mehmet Ali
dc.contributor.authorDemirci, Umut
dc.contributor.authorGoksu, Sema Sezgin
dc.date.accessioned2024-05-19T14:39:35Z
dc.date.available2024-05-19T14:39:35Z
dc.date.issued2024
dc.departmentİstinye Üniversitesien_US
dc.description.abstractAccording to current evidence, testing for germline BRCA pathogenic variants in newly diagnosed breast cancer (BC) patients has the potential to reduce the burden of the disease through targeted therapies and secondary prevention. A personalized approach to testing can lead to improved individual outcomes for patients. Despite the proven clinical utility and therapeutic impact of BRCA1/2 tests in shaping therapy for metastatic BC, awareness and access to these tests are limited in many developing countries, including Turkiye. This limitation impacts the healthcare economy as delayed or missed interventions can lead to increased long-term costs. The limited access is mainly due to fear of stigmatization among patients, country-specific legislation and costs, a lack of awareness, vagueness surrounding the tests and access restrictions. This review offers a perspective for policymakers and healthcare providers in Turkiye to establish pathways that integrate the patient experience into comprehensive care pathways and national cancer control plans.en_US
dc.description.sponsorshipPfizeren_US
dc.description.sponsorshipThis study was sponsored by Pfizer. B Aver and OF Ozturk Saglam are employees of Pfizer. The authors have no other relevant affiliations or financial involvement with any organization or entity with a financial interest in or financial conflict with the subject matter or materials discussed in the manuscript apart from those disclosed.en_US
dc.identifier.doi10.2217/fon-2023-0518
dc.identifier.issn1479-6694
dc.identifier.issn1744-8301
dc.identifier.issue15en_US
dc.identifier.pmid38014519en_US
dc.identifier.scopus2-s2.0-85189376763en_US
dc.identifier.scopusqualityQ1en_US
dc.identifier.urihttps://doi.org10.2217/fon-2023-0518
dc.identifier.urihttps://hdl.handle.net/20.500.12713/4811
dc.identifier.volume20en_US
dc.identifier.wosWOS:001114850700001en_US
dc.identifier.wosqualityN/Aen_US
dc.indekslendigikaynakWeb of Scienceen_US
dc.indekslendigikaynakScopusen_US
dc.language.isoenen_US
dc.publisherFuture Medicine Ltden_US
dc.relation.ispartofFuture Oncologyen_US
dc.relation.publicationcategoryMakale - Uluslararası Hakemli Dergi - Kurum Öğretim Elemanıen_US
dc.rightsinfo:eu-repo/semantics/openAccessen_US
dc.snmz20240519_kaen_US
dc.subjectBrca Pathogenic Varianten_US
dc.subjectBreast Canceren_US
dc.subjectGenetic Testingen_US
dc.subjectHealthcare Economyen_US
dc.subjectImproved Individual Outcomesen_US
dc.subjectPersonal Approachen_US
dc.titleGenetic testing and counseling challenges in personalized breast cancer care: review article with insights from Türkiyeen_US
dc.typeReview Articleen_US

Dosyalar

Koleksiyon

WoS İndeksli Yayınlar Koleksiyonu
PubMed İndeksli Yayınlar Koleksiyonu
Scopus İndeksli Yayınlar Koleksiyonu